RPRX Stock Analysis: Royalty Pharma | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 33.728m USD | 12M Return: 59.9% | GB00BMVP7Y09 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 177M
EPS Trend: 46.6%
Qual. Beats: 2
Rev. Trend: 66.8%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 6.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Royalty Pharma plc (NASDAQ: RPRX) is a New York-based biopharmaceutical royalty acquisition and innovation funding company founded in 1996. Its portfolio includes royalties on approximately 35 marketed therapies and 20 development-stage product candidates spanning therapeutic areas such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company also maintains a research and development funding collaboration to advance JNJ-4804, an investigational treatment for autoimmune diseases. As a large-cap health care company within the pharmaceuticals sub-industry, Royalty Pharma operates under a unique business model in which it purchases royalty interests on drug sales-rather than developing or commercializing drugs itself-providing upfront capital to biopharmaceutical innovators in exchange for a share of future product revenue. This royalty-based structure allows the company to participate in the upside of successful therapies without bearing the typical risks and costs of drug development and commercialization.
- Imfinzi and other key royalties drive portfolio cash flow growth
- New royalty acquisitions expand biopharmaceutical royalty pipeline
- Rising interest rates boost investment income on royalty portfolio
| Net Income: 815.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA 1.89 > 1.0 |
| NWC/Revenue: 7.14% < 20% (prev 13.61%; Δ -6.47% < -1%) |
| CFO/TA 0.15 > 3% & CFO 2.98b > Net Income 815.3m |
| Net Debt (8.12b) to EBITDA (1.72b): 4.74 < 3 |
| Current Ratio: 1.29 > 1.5 & < 3 |
| Outstanding Shares: last quarter (556.9m) vs 12m ago -0.96% < -2% |
| Gross Margin: 89.28% > 18% (prev 68.65%; Δ 20.63% > 0.5%) |
| Asset Turnover: 13.30% > 50% (prev 12.58%; Δ 0.72% > 0%) |
| Interest Coverage Ratio: 4.74 > 6 (EBIT TTM 1.71b / Interest Expense TTM 361.1m) |
| A: 0.01 (Total Current Assets 812.0m - Total Current Liabilities 630.9m) / Total Assets 19.8b |
| B: 0.12 (Retained Earnings 2.46b / Total Assets 19.8b) |
| C: 0.09 (EBIT TTM 1.71b / Avg Total Assets 19.1b) |
| D: 0.68 (Book Value of Equity 6.83b / Total Liabilities 10.0b) |
| Altman-Z'' = 1.78 = BBB |
As of October 06, 2026, the stock is trading at USD 56.66 with a total of 3,770,322 shares traded. Over the past week, the price has changed by -2.93%, over one month by -6.49%, over three months by -0.06% and over the past year by +59.86%.
Current recommended Stop Loss: 55.00 (which is 2.9% or 1.3 ATR below the current price).
Royalty Pharma has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy RPRX.
- StrongBuy: 4
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 65.1 | 14.9% |
P/E Trailing = 31.2139
P/E Forward = 29.4118
P/S = 13.2998
P/B = 3.7569
P/EG = 1.3431
Revenue TTM = 2.54b USD
EBIT TTM = 1.71b USD
EBITDA TTM = 1.72b USD
Long Term Debt = 8.58b USD (from longTermDebt, last quarter)
Short Term Debt = 380.0m USD (from shortTermDebt, last quarter)
Debt = 8.96b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 8.12b USD (calculated: Debt 8.96b - CCE 837.0m)
Enterprise Value = 41.9b USD (33.7b + Debt 8.96b - CCE 837.0m)
Interest Coverage Ratio = 4.74 (Ebit TTM 1.71b / Interest Expense TTM 361.1m)
EV/FCF = 14.06x (Enterprise Value 41.9b / FCF TTM 2.98b)
FCF Yield = 7.11% (FCF TTM 2.98b / Enterprise Value 41.9b)
FCF Margin = 117.4% (FCF TTM 2.98b / Revenue TTM 2.54b)
Net Margin = 32.15% (Net Income TTM 815.3m / Revenue TTM 2.54b)
Gross Margin = 89.28% ((Revenue TTM 2.54b - Cost of Revenue TTM 271.9m) / Revenue TTM)
Gross Margin QoQ = 60.21% (prev none%)
Tobins Q-Ratio = 2.11 (Enterprise Value 41.9b / Total Assets 19.8b)
Interest Expense / Debt = 4.03% (Interest Expense 361.1m / Debt 8.96b)
Taxrate = 0.0% (0.0 / 1.35b)
NOPAT = 1.71b (EBIT 1.71b * (1 - 0.00%))
Current Ratio = 1.29 (Total Current Assets 812.0m / Total Current Liabilities 630.9m)
Debt / Equity = 1.31 (Debt 8.96b / totalStockholderEquity, last quarter 6.83b)
Debt / EBITDA = 4.74 (Net Debt 8.12b / EBITDA 1.72b)
Debt / FCF = 2.73 (Net Debt 8.12b / FCF TTM 2.98b)
Total Stockholder Equity = 6.65b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.27% (Net Income 815.3m / Total Assets 19.8b)
RoE = 12.25% (Net Income TTM 815.3m / Total Stockholder Equity 6.65b)
RoCE = 11.23% (EBIT 1.71b / Capital Employed (Equity 6.65b + L.T.Debt 8.58b))
RoIC = 8.80% (NOPAT 1.71b / Invested Capital 19.4b)
WACC = 5.39% (E(33.7b)/V(42.7b) * Re(5.75%) + D(8.96b)/V(42.7b) * Rd(4.03%) * (1-Tc(0.0)))
Discount Rate = 5.75% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -94.81 | Cagr: -3.08%
[DCF] Terminal Value 77.97% ; FCFF base≈2.75b ; Y1≈3.15b ; Y5≈4.64b
[DCF] Fair Price = 138.5 (EV 69.8b - Net Debt 8.12b = Equity 61.7b / Shares 445.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 46.60 | EPS CAGR: 4.28% | SUE: 1.06 | # QB: 2
Revenue Correlation: 66.75 | Revenue CAGR: 2.84% | SUE: -0.33 | # QB: 0
EPS current Quarter (2026-09-30): EPS=1.18 | Chg30d=+1.64% | Revisions=+38% | Analysts=6
EPS current Year (2026-12-31): EPS=5.34 | Chg30d=+0.58% | Revisions=+67% | GrowthEPS=+10.6% | GrowthRev=+7.7%
EPS next Year (2027-12-31): EPS=5.73 | Chg30d=+0.92% | Revisions=+62% | GrowthEPS=+7.3% | GrowthRev=+8.7%
[Analyst] Revisions Ratio: +74% (up=15, down=1)